Related Experiment Video
Updated: Aug 12, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Comprehensive Characterization and Prognostic Modeling of Efferocytosis-Related Genes in Cutaneous Melanoma
Yuliang Sun1, Zhihu Ma1, Yanlin Li1
1Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, China, 250000.
Background:
Cutaneous melanoma (CM) is a highly aggressive skin cancer with poor prognosis in advanced stages. Efferocytosis, the process by which apoptotic cells are cleared by phagocytes, plays a dual role in tumor immunity and progression. However, the comprehensive role of efferocytosis-related genes (EFRGs) in CM remains unclear.
Methods:
We conducted a multi-omics analysis by integrating transcriptomic data from TCGA, GEO and GTEx databases, identifying differentially expressed genes and performing WGCNA to define EFRG signatures. Based on the expression profiles of differentially expressed EFRGs, we identified molecular subtypes, evaluated immune infiltration using ESTIMATE and ssGSEA. A prognostic EFRG risk scoring model was further constructed and validated using multiple machine learning algorithms. Western blot, CCK8 assay, colony formation assay and Transwell assays were performed to validate the functional role of the screened EFRG.
Results:
21 DE-EFRGs with significant prognostic value were identified and three distinct molecular subtypes were subsequently defined. The EFRG-based scoring model effectively stratified patients into high- and low-risk groups with distinct survival outcomes and immune microenvironment characteristics. The low-risk group exhibited a more immune-activated phenotype and greater sensitivity to immunotherapy and chemotherapeutic agents. In vitro functional validation revealed that knockdown of one screened EFRG, TTYH3, significantly inhibited melanoma cell proliferation and migration.
Conclusions:
Our study comprehensively characterizes EFRG patterns in CM and proposes a robust EFRG-based prognostic model. TTYH3 is identified as a potential oncogenic effector and therapeutic target. These findings may guide personalized immunotherapy and improve prognostic assessment in melanoma.

